These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
285 related articles for article (PubMed ID: 31278221)
1. Opportunities for Typhoid Vaccination in India. Srinivasan M; Sindhu KN; John J; Kang G Indian Pediatr; 2019 Jun; 56(6):453-458. PubMed ID: 31278221 [TBL] [Abstract][Full Text] [Related]
2. Comparison of Strategies and Incidence Thresholds for Vi Conjugate Vaccines Against Typhoid Fever: A Cost-effectiveness Modeling Study. Lo NC; Gupta R; Stanaway JD; Garrett DO; Bogoch II; Luby SP; Andrews JR J Infect Dis; 2018 Nov; 218(suppl_4):S232-S242. PubMed ID: 29444257 [TBL] [Abstract][Full Text] [Related]
3. The cost-effectiveness of typhoid Vi vaccination programs: calculations for four urban sites in four Asian countries. Cook J; Jeuland M; Whittington D; Poulos C; Clemens J; Sur D; Anh DD; Agtini M; Bhutta Z; Vaccine; 2008 Nov; 26(50):6305-16. PubMed ID: 18835415 [TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials. Bhutta ZA; Capeding MR; Bavdekar A; Marchetti E; Ariff S; Soofi SB; Anemona A; Habib MA; Alberto E; Juvekar S; Khan RM; Marhaba R; Ali N; Malubay N; Kawade A; Saul A; Martin LB; Podda A Lancet Infect Dis; 2014 Feb; 14(2):119-29. PubMed ID: 24290843 [TBL] [Abstract][Full Text] [Related]
5. A Phase II, Randomized, Double-blind, Controlled Safety and Immunogenicity Trial of Typhoid Conjugate Vaccine in Children Under 2 Years of Age in Ouagadougou, Burkina Faso: A Methods Paper. Laurens MB; Sirima SB; Rotrosen ET; Siribie M; Tiono A; Ouedraogo A; Liang Y; Jamka LP; Kotloff KL; Neuzil KM Clin Infect Dis; 2019 Mar; 68(Suppl 2):S59-S66. PubMed ID: 30845330 [TBL] [Abstract][Full Text] [Related]
6. Costs of illness due to typhoid fever in an Indian urban slum community: implications for vaccination policy. Bahl R; Sinha A; Poulos C; Whittington D; Sazawal S; Kumar R; Mahalanabis D; Acosta CJ; Clemens JD; Bhan MK J Health Popul Nutr; 2004 Sep; 22(3):304-10. PubMed ID: 15609783 [TBL] [Abstract][Full Text] [Related]
7. Typhoid Vaccine Acceleration Consortium Malawi: A Phase III, Randomized, Double-blind, Controlled Trial of the Clinical Efficacy of Typhoid Conjugate Vaccine Among Children in Blantyre, Malawi. Meiring JE; Laurens MB; Patel P; Patel P; Misiri T; Simiyu K; Mwakiseghile F; Tracy JK; Masesa C; Liang Y; Henrion M; Rotrosen E; Gmeiner M; Heyderman R; Kotloff K; Gordon MA; Neuzil KM Clin Infect Dis; 2019 Mar; 68(Suppl 2):S50-S58. PubMed ID: 30845320 [TBL] [Abstract][Full Text] [Related]
8. Evaluating investments in typhoid vaccines in two slums in Kolkata, India. Cook J; Sur D; Clemens J; Whittington D J Health Popul Nutr; 2009 Dec; 27(6):711-24. PubMed ID: 20099754 [TBL] [Abstract][Full Text] [Related]
9. Typhoid conjugate vaccines: a new tool in the fight against antimicrobial resistance. Andrews JR; Baker S; Marks F; Alsan M; Garrett D; Gellin BG; Saha SK; Qamar FN; Yousafzai MT; Bogoch II; Antillon M; Pitzer VE; Kim JH; John J; Gauld J; Mogasale V; Ryan ET; Luby SP; Lo NC Lancet Infect Dis; 2019 Jan; 19(1):e26-e30. PubMed ID: 30170987 [TBL] [Abstract][Full Text] [Related]
10. A forecast of typhoid conjugate vaccine introduction and demand in typhoid endemic low- and middle-income countries to support vaccine introduction policy and decisions. Mogasale V; Ramani E; Park IY; Lee JS Hum Vaccin Immunother; 2017 Sep; 13(9):2017-2024. PubMed ID: 28604164 [TBL] [Abstract][Full Text] [Related]
11. Typhoid vaccination: the Asian experience. DeRoeck D; Ochiai RL; Yang J; Anh DD; Alag V; Clemens JD Expert Rev Vaccines; 2008 Jul; 7(5):547-60. PubMed ID: 18564010 [TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of typhoid conjugate vaccines in five endemic low- and middle-income settings. Antillón M; Bilcke J; Paltiel AD; Pitzer VE Vaccine; 2017 Jun; 35(27):3506-3514. PubMed ID: 28527687 [TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of typhoid vaccination in India. Chauhan AS; Kapoor I; Rana SK; Kumar D; Gupta M; John J; Kang G; Prinja S Vaccine; 2021 Jul; 39(30):4089-4098. PubMed ID: 34120765 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of vi-tetanus toxoid conjugated typhoid vaccine (PedaTyph™) in Indian children: School based cluster randomized study. Mitra M; Shah N; Ghosh A; Chatterjee S; Kaur I; Bhattacharya N; Basu S Hum Vaccin Immunother; 2016 Apr; 12(4):939-45. PubMed ID: 26901576 [TBL] [Abstract][Full Text] [Related]
15. Typhoid fever vaccination strategies. Date KA; Bentsi-Enchill A; Marks F; Fox K Vaccine; 2015 Jun; 33 Suppl 3(Suppl 3):C55-61. PubMed ID: 25902360 [TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of routine and campaign use of typhoid Vi-conjugate vaccine in Gavi-eligible countries: a modelling study. Bilcke J; Antillón M; Pieters Z; Kuylen E; Abboud L; Neuzil KM; Pollard AJ; Paltiel AD; Pitzer VE Lancet Infect Dis; 2019 Jul; 19(7):728-739. PubMed ID: 31130329 [TBL] [Abstract][Full Text] [Related]
17. A cost-benefit analysis of typhoid fever immunization programmes in an Indian urban slum community. Poulos C; Bahl R; Whittington D; Bhan MK; Clemens JD; Acosta CJ J Health Popul Nutr; 2004 Sep; 22(3):311-21. PubMed ID: 15609784 [TBL] [Abstract][Full Text] [Related]
18. Typhoid vaccine: a case for inclusion in national program. Sharma P; Taneja DK Indian J Public Health; 2011; 55(4):267-71. PubMed ID: 22298135 [TBL] [Abstract][Full Text] [Related]
19. New generation typhoid vaccines: an effective preventive strategy to control typhoid fever in developing countries. Verma R; Bairwa M; Chawla S; Prinja S; Rajput M Hum Vaccin; 2011 Aug; 7(8):883-5. PubMed ID: 21791973 [TBL] [Abstract][Full Text] [Related]
20. Age for typhoid vaccination. John TJ Indian Pediatr; 1997 Jul; 34(7):649. PubMed ID: 9401263 [No Abstract] [Full Text] [Related] [Next] [New Search]